NewsNow Tube
UK Edition
Start trial
DISPATCH
Downing Street emergency council convenes on winter resilience • Bank of England monitoring gilt yield differentials • Thames Estuary flood barrier deployed for high tide surge

Search NewsNow Tube

NEW | IN DEPTH

Inside the UK institute developing an Alzheimer's disease blood test

Clinical researchers in Cambridge achieve landmark accuracy in detecting early plasma phosphorylated-tau biomarkers up to fifteen years before cognitive decline manifests.
NewsNow Medical Science Desk • Chief Health Correspondent Published October 23, 2026, 6:44 pm UTC • 1 min read
Inside the UK institute developing an Alzheimer's disease blood test
Laboratory automation at the Cambridge neurodegenerative research facility

In a clinical breakthrough that promises to reshape neurodegenerative medicine, scientists at the Cambridge Institute for Translational Neuroscience have validated a diagnostic blood assay capable of detecting Alzheimer's pathology with 96% diagnostic accuracy.

The test measures ultra-trace concentrations of phosphorylated tau-217 (p-tau217) in peripheral blood samples, eliminating the necessity for costly positron emission tomography (PET) imaging or invasive lumbar punctures.

Reader Responses (0)

Editorial moderation active

There are currently no published reader responses for this dispatch.

NewsNow Tube welcomes reasoned debate and informed analysis from verified readers.

Submit a Letter or Comment